Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaci.2016.10.030 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anti-inflammatory effects of LCB 03-0110 on human corneal epithelial and murine T helper 17 cells.
Korean J Physiol Pharmacol
November 2024
Division of Bio-Medical Science & Technology, KIST School, University of Science and Technology, Seoul 02792, Korea.
Dry eye disease (DED) is a complicated disorder that impacts ocular surface and tear-film stability. Inflammation has recently been reported as the core mechanism and main therapeutic target of DED. Although anti-inflammatory drugs have been developed, they still have limited efficacy and various side effects.
View Article and Find Full Text PDFTofacitinib Citrate Coordination-Based Dual-Responsive/Scavenge Nanoplatform Toward Regulate Colonic Inflammatory Microenvironment for Relieving Colitis.
Adv Healthc Mater
December 2024
Shanghai Frontier Science Center of Optogenetic Techniques for Cell Metabolism, School of Pharmacy, East China University of Science and Technology, Shanghai, 200237, China.
Ulcerative colitis is an inflammation of the colon characterized by immune dysregulation and intestinal inflammation. Developing safe oral nanomedicines that suppress intestinal inflammation, while modulating colonic inflammatory microenvironment by scavenging reactive oxygen species (ROS) and hydrogen sulfide (HS) is crucial for the effective treatment of colitis. Here, the tofacitinib citrate and copper coordination-based nanoparticle (TF-Cu nanoparticle, T-C) to dual-scavenge ROS and HS by coordination competition is synthesized.
View Article and Find Full Text PDFTofacitinib therapy in systemic lupus erythematosus with arthritis: a retrospective study.
Clin Rheumatol
October 2024
Department of Infectious Diseases, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian, China.
Objective: To estimate the effectiveness and safety of tofacitinib in treating systemic lupus erythematosus (SLE) patients with arthritis.
Methods: This research was a retrospective cohort study that focused on SLE patients who had arthritis and were treated with tofacitinib at the Department of Rheumatology and Immunology from January 2020 to January 2022. Clinical outcomes, disease activity, immunological parameters, and adverse events were systematically evaluated pre- and post-treatment at 4, 12, and 24 weeks.
In this paper, we present a case of relieving severe itching caused by scabies with tofacitinib. We show that the tofacitinib can quickly alleviate the itching caused by scabies, and this case may indicate a new option for comprehensive treatment of scabies.
View Article and Find Full Text PDFA novel drug combination of Tofacitinib and Iguratimod alleviates rheumatoid arthritis and secondary osteoporosis.
Int Immunopharmacol
November 2023
Qilu Hospital, Cheeloo College of Medicine, Shandong University, Department of Rheumatology, Jinan, China; Shandong Provincial Clinical Research Center for Immune Diseases and Gout, Department of Rheumatology, Qilu Hospital, Jinan, China. Electronic address:
Background: The inadequate response of some patients with rheumatoid arthritis (RA) to current therapies is an issue that needs to be addressed. Patients with refractory RA (RRA) are often accompanied by high Tumor necrosis factor (TNF) expression. We evaluated the synergistic therapeutic effects of the combination of Iguratimod (IGU) and Tofacitinib (TOF) on RRA and secondary osteoporosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!